Companies
Synthace
a University College London spinout that operated as a synthetic biology company before pivoting fully to software in 2017; its cloud-based Digital Experiment Platform automates design-of-experiments for complex biological processes, validated by AstraZeneca, GSK and Charles River.
- Country
- United Kingdom
Pharma-Validated
EU
Coverage
| CN | EU | US | |
|---|---|---|---|
| foundries-design | ✓ | ✓ | ✓ |
Regulatorsfdaema
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| CAD software for synthetic biology | foundries-design | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.